For the three months ended June 30, the point-of-care infectious disease diagnostics firm posted $4.1 million in total revenues, up from $3.3 million in Q2 2016.
The foundation will provide funding of no more than $20 million over the four-year term of the deal, and no more than $6 million each year.
The agency cleared a handful of assays last month for the detection and diagnoses of toxoplasmosis, syphilis, sepsis, thyroid conditions, and other ailments.
While molecular testing is now routine in cancer and women's health, for other disease areas, the technology may be overkill, Sundin said.
A total of 66 projects were awarded the funding as part of the Biomedical Catalyst 2016 funding.
As SpeeDx preps for the European launch of its STI tests, it will incorporate UgenTec's automated data analysis tool for PCR applications.
The firm is launching the test for bacterial vaginosis in Europe, the Middle East, and North Africa.
The real-time PCR test was developed by Thermo Fisher Scientific and validated by Aeon, and detects 34 different pathogens from vaginal swabs.
The US Preventive Services Task Force said that the potential harms resulting from screening for HSV outweigh the potential benefits.
The new women's health and STI tests for the BD Max platform are part of a small, focused panel approach which the firm believes will resonate with physicians and labs.